AstraZeneca's (AZN) Forxiga is Approved in Japan for Chronic Kidney Disease Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alexion's (AZN) ALXN1840 FoCus Phase III trial Met Primary Endpoint
August 26, 2021 5:35 AM EDTAstraZeneca's (NASDAQ: AZN) Alexion announces positive high-level results from the FoCus Phase III trial in Wilson disease.
ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments.
The primary endpoint gauged the daily mean Area Under the Effect Curve (AUEC) for directly measured non-ceruloplasmin-bound copper (dNCC) over 48 weeks. This novel measure assesses the daily mean copper mobilised from tissues, reflecting the underlying burden of the copper accumulation.
Wilson disease is a rare and progressive genetic... More
COVID vaccine protection wanes within six months - UK researchers
August 25, 2021 9:25 AM EDTBy William Schomberg and Ludwig Burger
LONDON (Reuters) -Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
After five to six months, the effectiveness of the Pfizer jab at preventing COVID-19 infection in the month after the second dose fell from 88% to 74%, an analysis of data collected in Britain's ZOE COVID study showed.
For the AstraZeneca vaccine, effectiveness fell from 77% to 67% after four to five months.
The study was... More
